revmed.com (RVMD) Company Sales Revenue

Revolution Medicines, Inc. - graphic logo of issuer RVMD

Revolution Medicines develops innovative treatments targeting RAS mutations for oncology centers. The company's product implementation clearly demonstrates the dynamics of this process, while the value of 0.20 reflects the current metric. The business relies on the search for therapies for terminal cases; however, investment success depends on clinical trial outcomes and the control of R&D expenses.

RVMD Revolution Medicines Corp: Company Sales in the range 07/04/2022 - 11/17/2026

Analytical breakdowns for Revolution Medicines

- market price and analyst price targets:
General company analysis:RVMD, Revolution Medicines, Inc.
Original product of Revolution Medicines Inc

To stress-test positions, it is critical for investors to monitor the daily inflow of commercial capital, which determines real liquidity and market interest in the asset. Amid fierce competition in oncology drug development, the consolidated sales of Revolution Medicines (RVMD) allow for an assessment of its operational resilience, highlighting the risk of frozen funds or business overvaluation against the backdrop of clinical trial risks.

Competing companies

Company Revenue ONC|Revenue and Sales Volume HALO|Revenue and Sales Volume Ascentage Pharma Group International (AAPG)|Revenue and Sales Volume CGON (CG Oncology Inc)|Company Sales Revenue URGN|bicara.com - Revenue and Sales Volume|Company Sales Revenue PSNL (personalis.com)|Erasca Inc (ERAS) - Company Revenue|Company Sales Delcath Systems|YMAB (YmAbs) - Revenue and Sales Volume|AURA: Company Sales Revenue|Company Revenue Candel Therapeutics, Inc. (CADL)|Revenue and Sales Volume Accuray (ARAY)|Company Revenue SELLAS Life Sciences Group Inc. SLS|Actuate Therapeutics, Inc (ACTU) - Company Total Revenue|CTOR - Company Revenue|HURA: Company Revenue|TARA (Protara) - Company Sales|Fate Therapeutics, Inc. - Company Sales Revenue|WHWK (aadibio.com) - Revenue and Sales Volume|TCRX: Company Sales Revenue|Company Revenue Champions Oncology (CSBR)|XBiotech - Company Sales Volume|Company Revenue CEL-SCI CVM|Company Gross Revenue OS Therapies (OSTX)|Radiopharm Theranostics Limited - Revenue and Sales Volume|Company Total Revenue Artiva Biotherapeutics|ANL (adlainortye.com) - Company Sales|Company Sales Veru Pharma|TPST (Tempest Therapeutics Inc) - Revenue and Sales Volume|Xilio Therapeutics, Inc. (XLO) - Company Gross Revenue|Company Revenue Enochian BioSciences (RENB)|MURA: Company Annual Revenue|Revenue and Sales Volume KAPA (kairospharma.com)|Company Gross Revenue OnKure (OKUR)|CytoMed Therapeutics Ltd - Revenue and Sales Volume|curis.com (CRIS) - Company Sales|Apollomics Corp (APLM) - Company Revenue|Tharimmune - Company Sales Revenue|ADVB (Advanced Biomed Corp) - Revenue and Sales Volume|Company Sales Genprex, Inc (GNPX)|Revenue and Sales Volume CLDI|SBFM: Company Annual Revenue|Revenue and Sales Volume XBIO (xeneticbio.com)|Revenue and Sales Volume Salarius Pharmaceuticals Inc SLRX|purple-biotech.com - Revenue and Sales Volume|Company Total Revenue American Oncology Network, Inc.|BGNE: Revenue and Sales Volume|Company Sales checkpointtx.com|Company Revenue Elevation Oncology, Inc.|iCAD, Inc. (ICAD) - Company Gross Revenue|Company Revenue Ikena (IKNA)|NTBL - Company Total Revenue|Company Revenue viracta.com VIRX|morphosys.com (MOR) - Company Total Revenue|NAYA Biosciences Inc - Revenue and Sales Volume|AAPGV: Company Revenue